TABLE. COVID-19 vaccines approved or authorized for emergency use by the Food and Drug Administration for persons aged ≥12 years — United States, October 2021*.
| COVID-19 vaccine manufacturer | Primary and additional primary doses |
Booster dose† |
|||||
|---|---|---|---|---|---|---|---|
| Age, yrs | Dose (volume) | No. of doses (interval between doses) | Additional primary dose in immunocompromised persons (interval since 2nd dose) | Interval between last primary (including additional) dose to booster dose | Dose (volume) | No. of doses | |
|
Pfizer-BioNTech (Comirnaty)
|
12–17 |
30 μg (0.3 ml) |
2 (21 days) |
1 (≥28 days) |
NA |
NA |
NA |
| ≥18§ |
30 μg (0.3 ml) |
2 (21 days) |
1 (≥28 days) |
≥6 months |
30 μg (0.3 ml) |
1 |
|
|
Moderna
|
≥18§ |
100 μg (0.5 ml) |
2 (28 days) |
1 (≥28 days) |
≥6 months |
50 μg (0.25 ml) |
1 |
| Janssen (Johnson & Johnson) | ≥18 | 5 × 1010 VP (0.5 ml) | 1 (NA) | NA | ≥2 months | 5 × 1010 VP (0.5 ml) | 1 |
Abbreviations: NA = not applicable; VP = viral particles.
* As of October 29, 2021. Food and Drug Administration package inserts or fact sheets provide updated information at https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines. Route of administration is intramuscular for the currently approved or authorized COVID-19 vaccines.
† The Advisory Committee on Immunization Practices recommends that any of the FDA-approved or authorized COVID-19 vaccines (Pfizer-BioNTech, Moderna, or Janssen) may be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous (mix-and-match) booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination. For example, a recipient of Janssen COVID-19 vaccine may receive a Pfizer-BioNTech, Moderna, or Janssen COVID-19 vaccine booster dose ≥2 months after their primary dose. A recipient of an mRNA COVID-19 primary series who is in a risk group recommended to receive a booster dose may receive a Pfizer-BioNTech, Moderna, or Janssen COVID-19 vaccine booster dose ≥6 months after completion of the primary series. Additional information on groups recommended for an additional primary or booster dose of COVID-19 vaccine is provided at https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.
§ Minimum authorized age group; see Advisory Committee on Immunization Practices’ recommendations for groups recommended to receive a booster dose.